Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients

Pharmacogenomics Journal

Volumn 12, Issue 3, 2012, Pages 238-245

  Weber, F ^a   Cepok, S ^b   Wolf, C ^a   Berthele, A ^b   Uhr, M ^a   Bettecken, Th ^a   Buck, D ^b   Hartung, H P ^c   Holsboer, F ^a   Muller Myhsok B ^a   Hemmer, B ^b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

association study; genetic risk; interferon b; multiple sclerosis; neutralizing antibodies; SNPs

Indexed keywords

BETA1A INTERFERON; HLA DR ANTIGEN; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLELE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHROMOSOME 8Q; COHORT ANALYSIS; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HLA DR GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 85027958957     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.14     Document Type: Article

References (29)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
2. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-1231. (Pubitemid 34304266)
3. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112(Part 1): 133-146. (Pubitemid 19056478)
4. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747. (Pubitemid 40563183)
5. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, de Jager PL et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862. (Pubitemid 47347319)
6. de Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41: 776-782.
7. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008; 9: 516-526. (Pubitemid 351861542)
8. Ann MR, Rudick RA. Drug insight: interferon treatment in multiple sclerosis. Nat Clin Pract Neurol 2006; 2: 34-44.
9. Bertolotto A, Deisenhammer F, Gallo P, Solberg SP. Immunogenicity of interferon beta: differences among products. J Neurol 2004; 251(Suppl 2): II15-II24: II15-II24.
10. Hemmer B, Stuve O, Kieseier B, Schellekens H, Hartung HP. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 2005; 4: 403-412. (Pubitemid 40826532)
11. Farrell RA, Giovannoni G. Measuring and management of antiinterferon beta antibodies in subjects with multiple sclerosis. Mult Scler 2007; 13: 567-577. (Pubitemid 46939521)
12. Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 2009; 73: 372-377.
13. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894.
14. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-1191. (Pubitemid 37255344)
15. Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40-47. (Pubitemid 40967774)
16. Francis GS, Rice GP, Alsop JC. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48-55. (Pubitemid 40967775)
17. Sorensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS task force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817-827. (Pubitemid 41597593)
18. Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68: 977-984. (Pubitemid 46569129)
19. Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010; 9: 740-750.
20. Hoffmann S, Cepok S, Grummel V, Lehmann-Horn K, Hackermuller J, Stadler PF et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008; 83: 219-227.
21. Pachner AR. An improved ELISA for screening for neutralizing anti-IFNbeta antibodies in MS patients. Neurology 2003; 61: 1444-1446. (Pubitemid 37463391)
22. Pachner A, Narayan K, Price N, Hurd M, Dail D. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003; 7: 17-25. (Pubitemid 37339029)
23. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 2009; 23: 379-396.
24. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002; 59: 1496-1506. (Pubitemid 35387053)
25. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A et al. Everyother-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-1460. (Pubitemid 34457761)
26. van der Voort LF, Gilli F, Bertolotto A, Knol DL, Uitdehaag BM, Polman CH et al. Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. Arch Neurol 2010; 67: 402-407.
27. Tilghman RW, Parsons JT. Focal adhesion kinase as a regulator of cell tension in the progression of cancer. Semin Cancer Biol 2008; 18: 45-52. (Pubitemid 350266368)
28. Stranger BE, Forrest MS, Clark AG, Minichiello MJ, Deutsch S, Lyle R et al. Genome-wide associations of gene expression variation in humans. PLoS Genet 2005; 1: e78.
29. Johnson AD, Handsaker RE, Pulit S, Nizzari MM, O'Donnell CJ, de Bakker PIW. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008; 24: 2938-2939.